We retrospectively investigated air-leak syndrome (ALS), including pneumothorax and mediastinal/s.c. emphysema, following allogeneic hematopoietic SCT. Eighteen patients (1.2%) developed ALS among 1515 undergoing SCT between 1994 and 2005 at the nine hospitals participating in the Kanto Study Group on Cell Therapy. The median onset of ALS was at 575 days (range: 105-1766) after SCT and 14 patients (77.8%) had experienced late onset noninfectious pulmonary complications (LONIPC) before ALS. Chronic GVHD (cGVHD) was the strongest risk factor for ALS (odds ratio 13.5, P ¼ 0.013 by multivariate analysis). Repeat SCT, male sex and age o38 years at the time of transplantation were also significant risk factors for ALS. Patients with ALS had a significantly worse survival rate than those without ALS (61.5 vs 14.9% at 3 years; P ¼ 0.000). The main cause of death was respiratory complications in 8 of the 18 patients. In conclusion, ALS is a rare complication of SCT that is more likely to occur in relatively young male patients with cGVHD and/or LONIPC. It is possible that better understanding and treatment of LONIPC may lead to prevention of ALS.
Introduction
The survival of patients with hematological disorders who receive allo-SCT has shown continuing improvement due to the introduction of various innovative therapeutic approaches. However, organ dysfunction/damage and infection remain problematic for long-term survivors after SCT, especially those with chronic GVHD (cGVHD), and such complications affect both their quality of life and survival. Late onset noninfectious pulmonary complications (LONIPC) are one of the most common manifestations of organ damage during the late phase after allo-SCT, [1] [2] [3] [4] [5] and have been reported to be the major cause of death for patients in this phase. Unlike LONIPC, airleak syndrome (ALS), which includes pneumothorax (PT), mediastinal emphysema (ME) and s.c. emphysema (SE), is a relatively rare complication of SCT. [6] [7] [8] [9] Although patients with ALS after SCT had a fatal outcome according to some case reports or small-scale retrospective studies, the clinical features of post transplant ALS remain obscure. The purpose of this study was to clarify the characteristics and risk factors for ALS after SCT, as well as its effect on survival.
Materials and methods

Patients
We retrospectively surveyed 1515 patients aged X15 years who received allo-SCT between January 1994 and March 2005 at nine hospitals participating in the Kanto Study Group on Cell Therapy (KSGCT) in Japan. Detailed clinical data were collected by reviewing the medical records of each institution, whereas baseline pretransplant and post transplant information on the patients was retrieved from the KSGCT database.
Definitions
Air-leak syndrome was diagnosed from chest X-ray films and/or computed tomography scans as follows: PT was diagnosed by detection of extra-alveolar air in the left and/ or right hemithorax, ME was defined as the presence of extra-alveolar air in the mediastinal space and SE was defined as extra-alveolar air in the s.c. tissue. Iatrogenic ALS that occurred after procedures such as trans-bronchial lung biopsy or mechanical ventilation was excluded. cGVHD and LONIPC were diagnosed from previously reported criteria. 10, 11 The case report form for ALS patients included the following information: date of diagnosis of ALS, type of ALS (described above), initial symptoms (cough, dyspnea and chest pain), presence of active cGVHD at the onset of ALS (yes or no), type of cGVHD (limited or extensive), presence of LONIPC (bronchiolitis obliterans (BO), bronchiolitis obliterans with organizing pneumonia (BOOP) and interstitial pneumonia (IP)), time from LONIPC to ALS, immunosuppressive therapy at the onset of ALS (prednisolone (PSL), CYA, tacrolimus (FK) and others), treatment of ALS (drain, initiate or increase the dose of immunosuppressive therapy, decrease the dose of immunosuppressive therapy, pleurodesis, observation and others), response to treatment (improved, stable or worsened), outcome and cause of death.
Statistical analysis
To identify risk factors for ALS, we tested the following variables by univariate and multivariate analyses: recipient age and sex, stem cell source, conditioning regimen (conventional vs reduced intensity), use of TBI, number of SCT procedures (first vs second or more), GVHD prophylaxis (CYA based vs FK based), grade of acute GVHD (0-I vs II-IV) and cGVHD (none vs limited or extensive). Comparison of categorical variables was carried out by the w 2 -test or Fisher's exact test, whereas comparison of continuous variables was performed with Student's t-test. To evaluate the independence of potential risk factors for ALS, we performed multiple logistic regression analysis. In all analyses, Po0.05 was considered to indicate statistical significance. Survival curves after the occurrence of ALS were estimated by the KaplanMeier method and the survival of patients with ALS was compared to that of those without ALS by the log-rank test, treating the occurrence of ALS as a timedependent variable. To determine whether ALS was an independent poor prognostic factor for long-term survival after SCT, we performed Cox proportional hazards analysis including the following variables: recipient age and sex, disease risk (standard risk diseases were acute leukemia in the first or second CR, aplastic anemia, refractory anemia, refractory anemia with ringed sideroblasts, CML in the first chronic phase, multiple myeloma in PR or CR and malignant lymphoma in the first or second CR, whereas all other diseases/states were considered to be high risk), stem cell source, type of conditioning regimen and use of TBI. Statistical analyses were performed with SPSS software (SPSS Inc., Chicago, IL, USA).
Results
Clinical features of ALS
Air-leak syndrome was diagnosed in 18 patients (1.2% of all patients) after allo-SCT. Table 1 shows a summary of the baseline characteristics of these patients. Sixteen patients were men and the median age was 29.5 years. Grade II-IV acute GVHD occurred in 11 patients (61%) and all but one patient (94%) had cGVHD. The clinical presentation and outcome of ALS are shown in Table 2 . The median time of onset was day 575 (range: days 105-1766) after SCT. ALS was classified as PT in seven patients, ME/SE in six patients and PT combined with ME/SE (mixed ALS) in five patients. At the onset of ALS, 16 patients had active cGVHD. Before ALS occurred, 14 patients had also experienced LONIPC, including 4 with BO, 4 with BOOP, 5 with IP and 1 with IP along with BOOP. At the diagnosis of ALS, LONIPC had resolved in two patients (nos. 5 and 18), but persisted in the remaining 12 patients. The median time from the diagnosis of LONIPC to the onset of ALS among the patients who had persistent LONIPC was 74 days (range: 3-1177 days). Seventeen patients (94%) had been treated with steroids and 13 patients (72%) were on steroids at the time of diagnosis of ALS. Treatment of ALS included drainage in 11 patients and pleurodesis in 3. ALS improved in 12 of 18 patients, remained stable in 2 patients and progressed despite treatment in 4 patients. The three patients (nos. 7, 12 and 13) who underwent pleurodesis all had progressive ALS ( Table 2) .
Eleven patients died at a median of 222 days after the occurrence of ALS (range: 6-944 days). Respiratory complications were the direct cause of death in eight patients, including ALS in four, BO in two and IP in two. Patient 10 did not have LONIPC before the occurrence of ALS, but BO appeared after improvement of ALS and became progressively worse. Two nonrespiratory deaths were attributable to relapse of the primary disease and one was due to multiple organ failure that was unrelated to ALS. Among the patients with PT or ME/ SE, seven out of nine who responded to treatment are still alive, whereas all four patients whose initial therapy At the diagnosis of ALS, LONIPC had already resolved.
ALS with allo-SCTfailed eventually died of LONIPC and/or ALS. In contrast, all five patients with mixed ALS died regardless of their responses to treatment and three of them died of progressive lung disease. For all 18 patients, OS at 1 year after the onset of ALS was 48.5 ± 12.1% and the 3-year survival rate was 18.2 ± 14.6% (Figure 1 ). Patients with PT and ME/SE showed better survival than did those with mixed ALS (59.8 vs 20.0% at 1 year and 29.9 vs 0% at 3 years, respectively; P ¼ 0.017; Figure 1 ). The patients without active LONIPC at the diagnosis of ALS (n ¼ 6) had a higher survival rate at 3 years than those with active LONIPC (53.3 vs 0%; P ¼ 0.15; data not shown).
Risk factors for ALS
Air-leak syndrome was always diagnosed more than 3 months after SCT in this study, so we compared the clinical features of patients with or without ALS who survived for more than 90 days after transplantation (1142 recipients). According to univariate analysis, ALS was significantly more frequent in recipients with cGVHD (P ¼ 0.001), those who received a second or subsequent SCT (P ¼ 0.043), younger recipients (P ¼ 0.013) and male recipients (P ¼ 0.013; data not shown). We also evaluated the risk factors for ALS by logistic regression analysis in 1047 recipients, after excluding 95 recipients (8.3%) because complete data were not available. The median age of the recipients was 38 years, so we divided them into two groups aged o38 and X38 years. Chronic GVHD was identified as the strongest risk factor for ALS (odds ratio (OR), 13.48; P ¼ 0.013), whereas second or subsequent SCT (OR, 7.91; P ¼ 0.021), male sex (OR, 4.95; P ¼ 0.038), age o38 years (OR, 3.55; P ¼ 0.033) and FK-based GVHD prophylaxis (OR, 3.3; P ¼ 0.025) were also identified as independent risk factors ( Table 3) .
Impact of ALS on OS
The patients with ALS had significantly lower survival rates (44.7% at 1 year and 14.9% at 3 years) compared with those without ALS (72.7% at 1 year and 61.5% at 3 years; P ¼ 0.002; Figure 2 ). We analyzed factors associated with lower OS among 1079 recipients who lived for more than 90 days after allo-SCT by multivariate Cox regression analysis (63 patients (5.5%) were excluded because of incomplete data). ALS was identified as an independent predictor of worse survival after SCT (OR, 3.468; P ¼ 0.001), as was a high-risk disease status (OR, 2.851; P ¼ 0.000) and an age X38 years (OR, 1.267; P ¼ 0.016; Table 4 ).
Discussion
All forms of thoracic air leak are defined as ALS according to Franquet et al., 12 including spontaneous pneumomediastinum or pneumopericardium, SE, interstitial emphysema and spontaneous PT. There have been only a few reports about ALS associated with SCT. Recently, Toubai et al. 8 performed a single-institution retrospective study and found ALS in 5 out of 213 recipients (2.3%) Patients with PT and ME/SE showed better survival than those with mixed ALS (P ¼ 0.017). 
Recipients with ALS showed significantly worse survival after SCT than those without ALS (P ¼ 0.002).
following allo-SCT, whereas Vogel et al. 9 reported ALS in 7 out of 300 recipients (2.3%). The incidence of ALS in the present study was slightly lower than in these previous studies. In this retrospective multicenter study, we tried to identify the characteristics, risk factors and prognosis of ALS after SCT, but the following limitations of our study must be considered. Unrecognized biases might have influenced the results of this retrospective study, especially as patients with asymptomatic ALS could not be detected. All cases of ALS were diagnosed more than 100 days after SCT in our series. Other studies and case reports have also shown that this complication occurs more than 100 days after SCT, [6] [7] [8] [9] and all authors have agreed that ALS can be classified as a late complication of allo-SCT.
We confirmed that cGVHD, second or subsequent SCT, male sex, age o38 years and FK-based GVHD prophylaxis were independent risk factors for ALS. Several case reports have indicated that ALS following SCT is associated with severe cGVHD or noninfectious pulmonary complications such as BO. 6, 9, 13, 14 In our series, 17 out of 18 recipients with ALS experienced cGVHD, and this is the first report to confirm statistically that the occurrence of ALS is strongly associated with cGVHD. It has also been reported that cGVHD is a significant risk factor for the development of LONIPC. [1] [2] [3] [4] In this series, most ALS patients also had LONIPC based on cGVHD. Although the mechanism leading to chronic pulmonary GVHD is unknown, it is thought that host-reactive donor T cells cause injury to the lungs. 15 Continuous inflammation due to cGVHD may lead to fibrotic change of the peripheral airways that decreases lung compliance. Chronic GVHD appears to cause the progression of LONIPC, resulting in the occurrence of ALS. Our recipients who received a second or subsequent SCT would have suffered pulmonary damage by the conditioning regimen, which could have contributed to the development of ALS, although the mechanism of lung injury differs from that of cGVHD. According to a review of the literature, 6, 7, 13, 14, 16, 17 ALS occurred after SCT in 17 men and 6 women with a median age of 30 years (range: 8-51 years). Our study confirmed by multivariate analysis that younger (o38 years old) men have a high risk of developing ALS after SCT. FK-based GVHD prophylaxis is generally chosen if stem cells are obtained from high-risk donors for GVHD, such as unrelated or HLA-mismatched related donors. This might explain the association between FK-based GVHD prophylaxis and development of ALS in our study.
The survival rate of patients after the occurrence of ALS was significantly impaired (18.2 ± 14.6% at 3 years), and the prognosis was related to the type of ALS (mixed ALS vs others). Alveolar rupture can occur because of an elevated intra-alveolar pressure, following damage to the alveolar walls, or for both reasons. 9 The subtypes of ALS reflect the extent of pulmonary/thoracic tissue damage, rather than different pathophysiological processes. This may explain the very poor outcome of mixed ALS. It is well known that the prognosis of secondary PT in patients with COPD is worse compared with idiopathic PT because it usually takes longer to reexpand the lung after a chest tube is inserted and failure of treatment is common. 16 It can be suggested that the onset of ALS in recipients with LONIPC leads to more severe lung tissue damage and a poor prognosis.
In conclusion, we were able to identify a subgroup of SCT recipients with a high risk of developing ALS, namely younger (o38 years) men with cGVHD, second or subsequent SCT and/or FK-based GVHD prophylaxis. As ALS is rare and its etiology is multifactorial, trials of new treatments are not feasible. A more promising strategy may be to improve our understanding and treatment of LONIPC, which should then lead to prevention of ALS. 
